vs
亚盛医药集团(AAPG)与Arbutus Biopharma Corp(ABUS)财务数据对比。点击上方公司名可切换其他公司
Arbutus Biopharma Corp的季度营收约是亚盛医药集团的1.8倍($1.1M vs $574.1K)
亚盛医药集团是一家全球性临床阶段生物技术企业,专注于开发用于治疗癌症、慢性病毒感染及衰老相关疾病的创新靶向药物,核心研发方向为靶向细胞凋亡通路的小分子药物,业务覆盖中、美等全球市场,致力于满足未被满足的临床需求。
Arbutus生物制药是一家公开上市的加拿大生物制药企业,专长于脂质体药物递送与RNA干扰技术,目前主要开展针对乙型肝炎感染的治疗药物研发工作,在抗病毒新药研发领域拥有深厚的技术积累。
AAPG vs ABUS — 直观对比
营收规模更大
ABUS
是对方的1.8倍
$574.1K
损益表 — Q4 2025 vs Q4 2025
| 指标 | ||
|---|---|---|
| 营收 | $574.1K | $1.1M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | — | -503.3% |
| 净利率 | — | — |
| 营收同比 | — | -33.2% |
| 净利润同比 | — | — |
| 每股收益(稀释后) | — | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
AAPG
ABUS
| Q4 25 | $574.1K | $1.1M | ||
| Q3 25 | — | $529.0K | ||
| Q2 25 | $32.6M | $10.7M | ||
| Q1 25 | — | $1.8M | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $1.7M | ||
| Q1 24 | — | $1.5M |
净利润
AAPG
ABUS
| Q4 25 | — | — | ||
| Q3 25 | — | $-7.7M | ||
| Q2 25 | $11.4M | $2.5M | ||
| Q1 25 | — | $-24.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-19.7M | ||
| Q2 24 | — | $-19.8M | ||
| Q1 24 | — | $-17.9M |
毛利率
AAPG
ABUS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 90.7% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率
AAPG
ABUS
| Q4 25 | — | -503.3% | ||
| Q3 25 | — | -1636.9% | ||
| Q2 25 | — | 13.9% | ||
| Q1 25 | — | -1456.9% | ||
| Q4 24 | — | -885.2% | ||
| Q3 24 | — | -1601.2% | ||
| Q2 24 | — | -1250.5% | ||
| Q1 24 | — | -1263.9% |
净利率
AAPG
ABUS
| Q4 25 | — | — | ||
| Q3 25 | — | -1463.5% | ||
| Q2 25 | — | 23.5% | ||
| Q1 25 | — | -1390.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1472.5% | ||
| Q2 24 | — | -1146.9% | ||
| Q1 24 | — | -1166.8% |
每股收益(稀释后)
AAPG
ABUS
| Q4 25 | — | $-0.01 | ||
| Q3 25 | — | $-0.04 | ||
| Q2 25 | — | $0.01 | ||
| Q1 25 | — | $-0.13 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | — | $-0.11 | ||
| Q1 24 | — | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | — | $91.5M |
| 总债务越低越好 | — | $0 |
| 股东权益账面价值 | — | $76.6M |
| 总资产 | — | $94.6M |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势,按日历期对齐
现金及短期投资
AAPG
ABUS
| Q4 25 | — | $91.5M | ||
| Q3 25 | — | $22.4M | ||
| Q2 25 | — | $37.4M | ||
| Q1 25 | — | $37.1M | ||
| Q4 24 | — | $122.6M | ||
| Q3 24 | — | $31.8M | ||
| Q2 24 | — | $62.8M | ||
| Q1 24 | — | $43.1M |
总债务
AAPG
ABUS
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
股东权益
AAPG
ABUS
| Q4 25 | — | $76.6M | ||
| Q3 25 | — | $77.4M | ||
| Q2 25 | — | $83.0M | ||
| Q1 25 | — | $79.2M | ||
| Q4 24 | — | $97.4M | ||
| Q3 24 | — | $106.9M | ||
| Q2 24 | — | $122.5M | ||
| Q1 24 | — | $114.6M |
总资产
AAPG
ABUS
| Q4 25 | — | $94.6M | ||
| Q3 25 | — | $97.7M | ||
| Q2 25 | — | $103.3M | ||
| Q1 25 | — | $117.0M | ||
| Q4 24 | — | $131.7M | ||
| Q3 24 | — | $140.4M | ||
| Q2 24 | — | $160.0M | ||
| Q1 24 | — | $150.3M |
负债/权益比
AAPG
ABUS
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | — | $-4.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势,按日历期对齐
经营现金流
AAPG
ABUS
| Q4 25 | — | $-4.7M | ||
| Q3 25 | — | $-5.8M | ||
| Q2 25 | — | $-15.7M | ||
| Q1 25 | — | $-13.4M | ||
| Q4 24 | — | $-10.3M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $-19.3M |
自由现金流
AAPG
ABUS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-10.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $-19.4M |
自由现金流率
AAPG
ABUS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -660.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -840.4% | ||
| Q1 24 | — | -1265.7% |
资本支出强度
AAPG
ABUS
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 5.5% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 6.2% |
现金转化率
AAPG
ABUS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -6.24× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图